^
    Back
    Association details:
    Biomarker:KRAS G12V
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    New
    Source:
    Clin Cancer Res
    Title:

    KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

    Excerpt:
    Each mutation was associated with worse DFS compared with KRAS/BRAF-wild type (all HR point estimates >1). Five of the six KRAS codon 12 mutations (c.34G>A [p.G12D], c.35G>T [p.G12V], c.34G>T [p.G12C], c.35G>C [p.G12A], c.34G>C [p.G12R]) demonstrated a statistically significant association with worse DFS in univariate and multivariate analysis.
    DOI:
    10.1158/1078-0432.CCR-13-3140
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A study to evaluate the efficacy and safety of SOT101 in combination with cetuximab in patients with a specific subtype of colon and/or rectum cancer Estudio para evaluar la eficacia y seguridad de SOT101 en combinación con cetuximab en pacientes con un subtipo específico de cáncer de colon y/o recto

    Excerpt:
    ...For the assessment of the RAS mutational status, a US Food and Drug Administration (FDA)-approved test or an experienced local laboratory using validated test methods for the detection of K-RAS and N-RAS (exons 2, 3, and 4) mutations must be used.6. ...
    Trial ID:
    2022-001527-32
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Cell Commun Signal
    Title:

    AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer

    Published date:
    07/23/2020
    Excerpt:
    The transfection of cells with mutant KRAS (G12V) resulted in significant suppression of their sensitivity to Cet and decreased the apoptosis of cells as compared with DLD1 WT cells…
    DOI:
    10.1186/s12964-020-00584-z
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    JAMA
    Title:

    Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

    Excerpt:
    In vitro and mouse model analysis showed that although p.G12V-mutated colorectal cells were insensitive to cetuximab, p.G13D-mutated cells were sensitive, as were KRAS wild-type cells.
    DOI:
    10.1001/jama.2010.1535